WO2007052274A3 - Magnetic resonance imaging and spectroscopy means and methods thereof - Google Patents

Magnetic resonance imaging and spectroscopy means and methods thereof Download PDF

Info

Publication number
WO2007052274A3
WO2007052274A3 PCT/IL2006/001268 IL2006001268W WO2007052274A3 WO 2007052274 A3 WO2007052274 A3 WO 2007052274A3 IL 2006001268 W IL2006001268 W IL 2006001268W WO 2007052274 A3 WO2007052274 A3 WO 2007052274A3
Authority
WO
WIPO (PCT)
Prior art keywords
agents
methods
metabolic
magnetic resonance
resonance imaging
Prior art date
Application number
PCT/IL2006/001268
Other languages
French (fr)
Other versions
WO2007052274A2 (en
Inventor
Rachel Katz-Brull
Original Assignee
Brain Watch Ltd
Rachel Katz-Brull
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brain Watch Ltd, Rachel Katz-Brull filed Critical Brain Watch Ltd
Priority to AU2006310100A priority Critical patent/AU2006310100B2/en
Priority to EP06809828A priority patent/EP1948248A2/en
Priority to CA002628608A priority patent/CA2628608A1/en
Priority to US12/092,763 priority patent/US20080287774A1/en
Priority to JP2008539605A priority patent/JP2009514946A/en
Publication of WO2007052274A2 publication Critical patent/WO2007052274A2/en
Publication of WO2007052274A3 publication Critical patent/WO2007052274A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

The present invention discloses neurochemical agents and biochemical agents for human or mammalian neuro- and body-metabolic imaging, comprising chemicals involved in neuronal or glial function, neuromodulatory processes in the brain of said human or mammalian, vascular function, or organ specific metabolic processes; said neurochemical and biochemical agents are labeled with stable isotopes selected from a group including carbon-13, nitrogen-15, deuterium, fluorine-19 or a combination thereof in predetermined positions, so as to enhance the detectability of the agents and their metabolic successors.
PCT/IL2006/001268 2005-11-06 2006-11-02 Magnetic resonance imaging and spectroscopy means and methods thereof WO2007052274A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2006310100A AU2006310100B2 (en) 2005-11-06 2006-11-02 Magnetic resonance imaging and spectroscopy means and methods thereof
EP06809828A EP1948248A2 (en) 2005-11-06 2006-11-02 Magnetic resonance imaging and spectroscopy means and methods thereof
CA002628608A CA2628608A1 (en) 2005-11-06 2006-11-02 Magnetic resonance imaging and spectroscopy means and methods thereof
US12/092,763 US20080287774A1 (en) 2005-11-06 2006-11-02 Magnetic Resonance Imaging and Spectroscopy Means and Methods Thereof
JP2008539605A JP2009514946A (en) 2005-11-06 2006-11-02 Magnetic resonance imaging / spectral means and method thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL171790 2005-11-06
IL17179005 2005-11-06

Publications (2)

Publication Number Publication Date
WO2007052274A2 WO2007052274A2 (en) 2007-05-10
WO2007052274A3 true WO2007052274A3 (en) 2009-04-09

Family

ID=38006296

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2006/001268 WO2007052274A2 (en) 2005-11-06 2006-11-02 Magnetic resonance imaging and spectroscopy means and methods thereof

Country Status (6)

Country Link
US (1) US20080287774A1 (en)
EP (1) EP1948248A2 (en)
JP (1) JP2009514946A (en)
AU (1) AU2006310100B2 (en)
CA (1) CA2628608A1 (en)
WO (1) WO2007052274A2 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1954669B1 (en) * 2005-12-01 2015-07-08 Auspex Pharmaceuticals, Inc. Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
WO2008021891A2 (en) * 2006-08-08 2008-02-21 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted quinazoline compounds with alpha-adrenergic blocking effects
TW200846305A (en) * 2007-03-15 2008-12-01 Auspex Pharmaceuticals Inc Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
US20110243855A1 (en) * 2007-08-27 2011-10-06 Anna Gisselsson Method and imaging medium for use in the method
US20110008261A1 (en) * 2008-02-04 2011-01-13 Ge Healthcare Limited Method to produce hyperpolarised amino acids and aminosulphonic acids
US20090209550A1 (en) * 2008-02-20 2009-08-20 Auspex Pharmaceuticals, Inc. Substituted triazolopyridines
US8694073B2 (en) * 2008-10-15 2014-04-08 University Of Utah Research Foundation Predicting efficacy of psychiatric treatment
US20100129290A1 (en) * 2008-11-26 2010-05-27 I.S.T. Corporation Smart contrast agent and detection method for detecting transition metal ions
US20100311710A1 (en) * 2008-12-06 2010-12-09 Auspex Pharmaceuticals, Inc. Cyclobutanemethanamine inhibitors of monoamine reuptake
WO2010077730A2 (en) * 2008-12-09 2010-07-08 Auspex Pharmaceutical, Inc Indanone inhibitors of acetylcholinesterase
US9512104B2 (en) 2009-07-28 2016-12-06 Auspex Pharmaceuticals, Inc. Quinolone inhibitors of lipoprotein-associated phospholipase A2
US8637524B2 (en) 2009-07-28 2014-01-28 Auspex Pharmaceuticals, Inc Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2
US8575348B2 (en) * 2009-07-28 2013-11-05 Auspex Pharmaceuticals, Inc Quinolone inhibitors of lipoprotein-associated phospholipase A2
WO2011024156A1 (en) 2009-08-31 2011-03-03 Brain Watch Ltd. Isotopically labeled neurochemical agents and uses thereof for diagnosing conditions and disorders
CN102892434B (en) 2010-04-08 2014-11-19 伯拉考成像股份公司 Process for preparing hyperpolarized substrates and method for mri
WO2012056447A1 (en) * 2010-10-25 2012-05-03 Brain Watch Ltd. Isotopically labeled deoxy-glucose and derivatives thereof, compositions comprising them and uses thereof
EA201390613A1 (en) * 2010-10-26 2013-11-29 Тева Фармасьютикал Индастриз Лтд. Enriched by rasagiline deuterium
US9074237B2 (en) * 2011-04-13 2015-07-07 Stc.Unm Method for diagnosing Francisella tularensis infection
WO2012145733A1 (en) 2011-04-22 2012-10-26 Vanderbilt University Para-hydrogen polarizer
US20140099262A1 (en) * 2011-06-01 2014-04-10 Brain Watch Ltd. Isotopically labeled cdp-choline and uses thereof
US20130017163A1 (en) 2011-07-14 2013-01-17 Latham Keith R Halogenated phenols for diagnostics, antioxidant protection and drug delivery
US10220100B2 (en) 2011-07-14 2019-03-05 Keith R. Latham Halogenated phenols for diagnostics, antioxidant protection and drug delivery
EP2551675A1 (en) * 2011-07-28 2013-01-30 Chiron AS Deuterium free, stable isotope labeled 2-phenylethylamine hallucinogens and/or stimulants, methods fo their preparation and their use
WO2013049112A1 (en) * 2011-09-27 2013-04-04 Emory University Detection of biomarkers using magnetic resonance
US9511154B2 (en) 2011-10-12 2016-12-06 Bracco Imaging S.P.A. Process for the preparation of hyperpolarized derivatives for use in MRI analysis
EP2788035B1 (en) 2011-12-05 2016-03-09 Bracco Imaging S.p.A Composition comprising acetic anhydride and a gadolinium complex, and method for the use in hyperpolarisation mri analysis
EP2833924B1 (en) 2012-04-02 2019-05-08 Bracco Imaging S.p.A Hyperpolarized amino acids
US9329245B2 (en) * 2012-04-11 2016-05-03 Bruker Biospin Ag MRI compatible method and device for rapid DNP on a solid state hyperpolarized sample material
WO2014009240A1 (en) 2012-07-13 2014-01-16 Bracco Imaging Spa Triarylmethyl radicals
PT3261645T (en) 2015-02-27 2021-06-17 Dechra Ltd Stimulation of appetite, management of weight loss, and treatment of anorexia in dogs and cats
WO2019060298A1 (en) 2017-09-19 2019-03-28 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement
JP6571149B2 (en) * 2017-11-20 2019-09-04 国立大学法人京都大学 Multiple resonance probe
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
EP3731749A4 (en) 2017-12-31 2022-07-27 Neuroenhancement Lab, LLC System and method for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
JP7224642B2 (en) * 2018-07-17 2023-02-20 学校法人九州文化学園 Measuring method and measuring device
CN113382683A (en) 2018-09-14 2021-09-10 纽罗因恒思蒙特实验有限责任公司 System and method for improving sleep
EP3883612A4 (en) * 2018-11-21 2021-09-29 The University Of Georgia Research Foundation, Inc. Bimodal nanoparticle conjugates for non-invasive central nervous system tissue imaging
JP7111310B2 (en) 2019-12-11 2022-08-02 日本電子株式会社 Nuclear magnetic resonance measurement method and apparatus
US20220134122A1 (en) * 2020-11-05 2022-05-05 Bradley Zang Method of Treatment Using Nuclear Magnetic Photon Excitation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6617169B2 (en) * 2001-03-30 2003-09-09 Mclean Hospital Corporation Two-dimensional MR spectroscopy techniques

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6278893B1 (en) * 1998-01-05 2001-08-21 Nycomed Imaging As Method of magnetic resonance imaging of a sample with ex vivo polarization of an MR imaging agent
WO2001089584A2 (en) * 2000-05-23 2001-11-29 Amersham Health As Contrast agents
GB0014463D0 (en) * 2000-06-14 2000-08-09 Nycomed Amersham Plc NMR Method
GB0122049D0 (en) * 2001-09-12 2001-10-31 Nycomed Imaging As Method
NO20035626D0 (en) * 2003-12-17 2003-12-17 Amersham Health As Method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6617169B2 (en) * 2001-03-30 2003-09-09 Mclean Hospital Corporation Two-dimensional MR spectroscopy techniques

Also Published As

Publication number Publication date
WO2007052274A2 (en) 2007-05-10
AU2006310100B2 (en) 2012-12-06
EP1948248A2 (en) 2008-07-30
US20080287774A1 (en) 2008-11-20
JP2009514946A (en) 2009-04-09
AU2006310100A2 (en) 2008-08-07
AU2006310100A1 (en) 2007-05-10
CA2628608A1 (en) 2007-05-10

Similar Documents

Publication Publication Date Title
WO2007052274A3 (en) Magnetic resonance imaging and spectroscopy means and methods thereof
Angelova et al. Lipid peroxidation is essential for α‐synuclein‐induced cell death
Frazier et al. Isothermal titration calorimetry study of epicatechin binding to serum albumin
GB2433602B (en) Combined titration and pH electrode for the preparation of liquid samples in particular for NMR spectroscopy
WO2010009987A3 (en) Diagnostic antibody assay
WO2008030273A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2007044867A3 (en) Imaging agents and methods of use thereof
EP1908041A4 (en) Local intercept methods, such as applications for providing customer assistance for training, information calls and diagnostics
WO2005084390A3 (en) Partially loaded antibodies and methods of their conjugation
EA200701500A1 (en) METHODS OF OBTAINING PYRAZOLO [3,4-d] Pyrimidine esters
NO20083153L (en) Chemical connections
WO2006036173A3 (en) Frizzled proteins and detection and treatment of cancer
SG155931A1 (en) Wnt proteins and detection and treatment of cancer
BRPI0606481A2 (en) vaccine composition comprising a fibronectin binding protein or a fibronectin binding peptide
WO2006034328A3 (en) Wnt proteins and detection and treatment of cancer
ATE542914T1 (en) PRODUCTION OF HIGHLY ISOTOPICALLY LABELED SECONDARY MICROBIAL METABOLIC METABOLIC PRODUCTS AND CORRESPONDING METABOLISM PRODUCTS
GB0718957D0 (en) Optical imaging agents
Xiao et al. Local unfolding of fatty acid binding protein to allow ligand entry for binding
ATE443529T1 (en) CONTRAST AGENTS FOR MAGNETIC RESONANCE TOMOGRAPHY
WO2011051805A8 (en) Methods and systems for identifying molecules or processes of biological interest by using knowledge discovery in biological data
WO2006117166A3 (en) Mri contrast agents endowed with concentration independent responsiveness
WO2006094134A3 (en) Kim-1 antibodies for treatment of th2-mediated conditions
WO2008063779A3 (en) Cells expressing alpha-synuclein and uses therefor
WO2008040882A3 (en) Method of diagnosing neuropsychiatric diseases, eating disorders or metabolic diseases
WO2008014296A3 (en) Composition and method for treatment of tumors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2628608

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2008539605

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12092763

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2006809828

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006310100

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2006310100

Country of ref document: AU

Date of ref document: 20061102

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006310100

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006809828

Country of ref document: EP